Table 3.
Baseline univariate predictors of survival in tocilizumab patients.
| Survived (27 patients) | Dead (5 patients) | p-value | |
|---|---|---|---|
| Age (years), median (IQR) | 61 (53 – 73) | 77 (74 – 81) | 0.003 |
| Sex (male), n (%) | 25 (93) | 4 (80) | 0.41 |
| PaO2:FiO2, median (IQR) | 118 (86 – 181) | 69 (65 – 94) | 0.034 |
| Body temperature (°C), median (IQR) | 37.5 (38.9 – 38.2) | 38 (37.5 – 38) | 0.85 |
| CRP (mg/L), median (IQR) | 139 (88.5 – 204) | 185 (146 – 185) | 0.46 |
| LDH (U/L), median (IQR) | 439 (357 – 546) | 443 (438 – 456) | 0.94 |
| NIV, n (%) | 20 (74) | 5 (100) | 0.56 |
| Duration of symptoms (days), median (IQR) | 11 (7 – 14) | 12 (9 – 15) | 0.36 |
| CKD, n (%) | 3 (9) | 0 | 0.99 |
| Arterial hypertesion, n (%) | 11 (34) | 1 (20) | 0.63 |
| COPD, n (%) | 0 | 1 (20) | 0.16 |
| Cancer, n (%) | 2 (7) | 0 | 0.99 |
| T2DM, n (%) | 3 (11) | 1 (20) | 0.51 |
| CAD, n (%) | 2 (7) | 2 (40) | 0.10 |
| Re-treatment, n (%) | 8 (30) | 1 (20) | 0.99 |
NIV = non-invasive ventilation. CRP = C-reactive protein. LDH = lactate dehydrogenase. CKD = chronic kidney disease. COPD = chronic obstructive pulmonary disease. T2DM = type-2 diabetes mellitus. CAD = coronary artery disease.